InChI=1S/C20H32O6/c1- 2- 3- 4- 7- 14(21) 10- 11- 16- 17(19(24) 13- 18(16) 23) 12- 15(22) 8- 5- 6- 9- 20(25) 26/h10- 11,14,16- 18,21,23H,2- 9,12- 13H2,1H3,(H,25,26) /b11- 10+/t14- ,16+,17+,18+/m0/s1 |
ROUDCKODIMKLNO-CTBSXBMHSA-N |
CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CC(=O)CCCCC(O)=O |
|
metabolite
Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
|
|
platelet aggregation inhibitor
A drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
|
|
View more via ChEBI Ontology
(13E,15S)-11α,15-dihydroxy-6,9-dioxoprost-13-en-1-oic acid
|
6-Keto-PGE1
|
KEGG COMPOUND
|
6-Keto-prostaglandin E1
|
KEGG COMPOUND
|
6-Ketoprostaglandin E1
|
ChemIDplus
|
6-Oxo-PGE1
|
ChemIDplus
|
6-Oxoprostaglandin E1
|
ChemIDplus
|
2904839
|
Reaxys Registry Number
|
Reaxys
|
67786-53-2
|
CAS Registry Number
|
ChemIDplus
|
2858551
|
PubMed citation
|
Europe PMC
|
3240016
|
PubMed citation
|
Europe PMC
|
3881101
|
PubMed citation
|
Europe PMC
|
6132981
|
PubMed citation
|
Europe PMC
|
6360281
|
PubMed citation
|
Europe PMC
|
|